The past 18 months have included 3 drug approvals in the United States for the treatment of patients with hepatocellular carcinoma (HCC), with additional targeted therapies and checkpoint inhibitors in late stages of development. Moreover, the oncology community is awaiting later-phase data that will undoubtedly impact treatment decisions, explained Morris Sherman, MD, PhD.

Read the full article

View more articles from the 12th ILCA Annual Conference